Yan Wang1, Fengyan Pei2, Xingjuan Wang1, Zhiyu Sun1, Chengjin Hu1, Hengli Dou3. 1. Department of Laboratory Medicine, General Hospital of Ji'nan Military Area Ji'nan 250031, Shandong Province, China. 2. Department of Laboratory Medicine, Ji'nan Central Hospital Ji'nan 250013, Shandong Province, China. 3. Division of Chest Disease, The Fourth Hospital of Ji'nan Ji'nan 250013, Shandong Province, China.
Abstract
OBJECTIVE: To do a systematic review using meta-analysis to assess the diagnostic accuracy of fecal lactoferrin (FL) in patients with inflammatory bowel disease (IBD). METHODS: We performed a literature review and systematically searched the Medline and EMBASE databases for eligible studies. The quality of the included studies was assessed using the QUADAS tool. The sensitivity, specificity, and other diagnostic indexes of FL were pooled using a random-effects model. RESULTS: Seven studies, involving 1816 patients, met the inclusion criteria. In all studies, the pooled FL sensitivity and pooled specificity were 0.82 (95% confidence interval [CI]: 0.72, 0.89) and 0.95 (95% CI: 0.88, 0.98), respectively. The positive and negative likelihood ratios were 16.63 and 0.18, respectively. The area under the summary receiver-operating characteristic curve (SROC) was 0.95 (95% CI: 0.93, 0.97), and the diagnostic odds ratio was 90.04 (95% CI: 37.01, 219.02). The pooled FL sensitivity and specificity for Crohn's disease (CD) diagnosis (sensitivity =75%, specificity =100%) was not as good as it was for ulcerative colitis (UC) diagnosis (sensitivity =82%, specificity =100%). CONCLUSION: FL, as a noninvasive and screening marker, has a high specificity and a modest specificity during the diagnosis of suspected IBD.
OBJECTIVE: To do a systematic review using meta-analysis to assess the diagnostic accuracy of fecal lactoferrin (FL) in patients with inflammatory bowel disease (IBD). METHODS: We performed a literature review and systematically searched the Medline and EMBASE databases for eligible studies. The quality of the included studies was assessed using the QUADAS tool. The sensitivity, specificity, and other diagnostic indexes of FL were pooled using a random-effects model. RESULTS: Seven studies, involving 1816 patients, met the inclusion criteria. In all studies, the pooled FL sensitivity and pooled specificity were 0.82 (95% confidence interval [CI]: 0.72, 0.89) and 0.95 (95% CI: 0.88, 0.98), respectively. The positive and negative likelihood ratios were 16.63 and 0.18, respectively. The area under the summary receiver-operating characteristic curve (SROC) was 0.95 (95% CI: 0.93, 0.97), and the diagnostic odds ratio was 90.04 (95% CI: 37.01, 219.02). The pooled FL sensitivity and specificity for Crohn's disease (CD) diagnosis (sensitivity =75%, specificity =100%) was not as good as it was for ulcerative colitis (UC) diagnosis (sensitivity =82%, specificity =100%). CONCLUSION: FL, as a noninvasive and screening marker, has a high specificity and a modest specificity during the diagnosis of suspected IBD.
Authors: Reena Sidhu; David S Sanders; Perm Wilson; Laura Foye; Stephen Morley; Mark E McAlindon Journal: J Gastrointestin Liver Dis Date: 2010-09 Impact factor: 2.008
Authors: J Panes; Y Bouhnik; W Reinisch; J Stoker; S A Taylor; D C Baumgart; S Danese; S Halligan; B Marincek; C Matos; L Peyrin-Biroulet; J Rimola; G Rogler; G van Assche; S Ardizzone; A Ba-Ssalamah; M A Bali; D Bellini; L Biancone; F Castiglione; R Ehehalt; R Grassi; T Kucharzik; F Maccioni; G Maconi; F Magro; J Martín-Comín; G Morana; D Pendsé; S Sebastian; A Signore; D Tolan; J A Tielbeek; D Weishaupt; B Wiarda; A Laghi Journal: J Crohns Colitis Date: 2013-04-11 Impact factor: 9.071
Authors: Paul J Limburg; Mary E Devens; Jonathan J Harrington; Nancy N Diehl; Douglas W Mahoney; David A Ahlquist Journal: Am J Gastroenterol Date: 2003-10 Impact factor: 10.864
Authors: Viktor Grünwald; Martin H Voss; Brian I Rini; Thomas Powles; Laurence Albiges; Rachel H Giles; Eric Jonasch Journal: Br J Cancer Date: 2020-06-26 Impact factor: 7.640
Authors: Fangwen Zou; Xuemei Wang; Isabella C Glitza Oliva; Jennifer L McQuade; Jennifer Wang; Hao Chi Zhang; John A Thompson; Anusha S Thomas; Yinghong Wang Journal: J Immunother Cancer Date: 2021-01 Impact factor: 13.751
Authors: John Gubatan; Derek R Holman; Christopher J Puntasecca; Danielle Polevoi; Samuel Js Rubin; Stephan Rogalla Journal: World J Gastroenterol Date: 2021-11-21 Impact factor: 5.742